Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies	Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, bladder urachal carcinoma, carcinoma, epithelial neoplasm, extramammary Paget disease, neoplasm	Recruiting	Phase 2	2025-12-30		NCT07309770

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sheng Zhang	4

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fudan University Shanghai Cancer Center	Shanghai	China	13

Clinical trials